WallStSmart

Quanta Services Inc (PWR)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Quanta Services Inc generates 835% more annual revenue ($30.12B vs $3.22B). WST leads profitability with a 16.9% profit margin vs 3.7%. PWR appears more attractively valued with a PEG of 2.43. WST earns a higher WallStSmart Score of 67/100 (B-).

PWR

Buy

54

out of 100

Grade: C-

Growth: 8.7Profit: 5.0Value: 3.7Quality: 5.0

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for PWR.

WSTSignificantly Overvalued (-32.8%)

Margin of Safety

-32.8%

Fair Value

$185.39

Current Price

$312.55

$127.16 premium

UndervaluedFair: $185.39Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PWR3 strengths · Avg: 9.0/10
EPS GrowthGrowth
51.0%10/10

Earnings expanding 51.0% YoY

Market CapQuality
$113.65B9/10

Large-cap with strong market position

Revenue GrowthGrowth
26.3%8/10

Revenue surging 26.3% year-over-year

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

PWR4 concerns · Avg: 3.5/10
PEG RatioValuation
2.434/10

Expensive relative to growth rate

Price/BookValuation
13.1x4/10

Trading at 13.1x book value

Profit MarginProfitability
3.7%3/10

3.7% margin — thin

Operating MarginProfitability
4.2%3/10

Operating margin of 4.2%

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
2.892/10

Expensive relative to growth rate

P/E RatioValuation
40.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : PWR

The strongest argument for PWR centers on EPS Growth, Market Cap, Revenue Growth. Revenue growth of 26.3% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : PWR

The primary concerns for PWR are PEG Ratio, Price/Book, Profit Margin. A P/E of 102.1x leaves little room for execution misses. Thin 3.7% margins leave little buffer for downturns.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 40.1x leaves little room for execution misses.

Key Dynamics to Monitor

PWR carries more volatility with a beta of 1.24 — expect wider price swings.

PWR is growing revenue faster at 26.3% — sustainability is the question.

PWR generates stronger free cash flow (172M), providing more financial flexibility.

Monitor ENGINEERING & CONSTRUCTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

WST scores higher overall (67/100 vs 54/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Quanta Services Inc

INDUSTRIALS · ENGINEERING & CONSTRUCTION · USA

Quanta Services is an American corporation that provides infrastructure services for electric power, pipeline, industrial and communications industries. Capabilities include the planning, design, installation, program management, maintenance and repair of most types of network infrastructure.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?